泰恩康(301263.SZ):創新藥管線有治療白癜風的CKBA軟膏,現正在開展II期臨牀研究
格隆匯8月7日丨泰恩康(301263.SZ)在投資者互動平台表示,公司的創新藥管線有治療白癜風的CKBA軟膏,現正在開展II期臨牀研究。今年7月,國務院常務會議通過《全鏈條支持創新藥發展實施方案》,指出要全鏈條強化政策保障,統籌用好價格管理、醫保支付、商業保險、藥品配備使用、投融資等政策,優化審評審批和醫療機構考核機制,合力助推創新藥突破發展。要調動各方面科技創新資源,強化新藥創制基礎研究,夯實我國創新藥發展根基。此番方案的通過,有望進一步激發產業創新活力,公司也將積極根據政策,加快、穩步推進項目進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.